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Abstract
© 2017 Mikhail  V. Pugachev et al.  A series of trans-6-phenylethenyl substituted pyridoxine
derivatives,  novel  bioisosteric  analogs  of  drugs  based  on  trans-stilbene  scaffold,  were
synthesized using the Wittig reaction of a bis-triphenylphosphonium pyridoxine derivative with
various aromatic aldehydes. Two compounds demonstrated high activity against the estrogen-
dependent MCF-7 (breast cancer) cell line with IC 50 in the range of 1.9-7.9 μM and very good
selectivity for other studied normal and tumor cells, including the estrogen receptor negative
MDA-MB-231  breast  cancer  cells.  The  active  compounds  possessed  an  intense  blue
fluorescence, and this feature allowed us to effectively visualize them in cytoplasm and in
nucleus. The obtained results make the described chemotype a promising starting point for the
development of new anticancer agents for the therapy of estrogen-dependent malignancies.
http://dx.doi.org/10.1155/2017/8281518
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